Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.

Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.

The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.

Company believes its oral HAE prophylaxis will gradually reach the billion-dollar sales threshold, with about 80% of revenue coming from the US market.